Research Topics
| Celestia S HiganoSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Side effects of androgen deprivation therapy: monitoring and minimizing toxicityCelestia S Higano
Department of Urology, University of Washington School of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
Urology 61:32-8. 2003..These side effects need more systematic study in clinical trials. Physicians should be aware of far-reaching consequences of ADT and should incorporate strategies for preventing and managing toxicities into routine practice...
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu
University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Clin Oncol 30:1864-70. 2012..To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer...- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthR Bruce Montgomery
Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
Cancer Res 68:4447-54. 2008..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment... - Metastases of prostate cancer express estrogen receptor-betaJanice S Lai
Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
Urology 64:814-20. 2004..05) was detected. CONCLUSIONS: Our data have shown that ERbeta is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP... - Histopathological assessment of prostate cancer bone osteoblastic metastasesMartine P Roudier
Department of Pathology, University of Washington and Research Service, Seattle, Washington, USA
J Urol 180:1154-60. 2008..The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases... - Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu
Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
J Clin Oncol 28:2668-73. 2010.... - Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastasesColm Morrissey
Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
Clin Exp Metastasis 25:377-88. 2008..In addition, the resulting tumor-associated microvessel density and distribution was significantly different between liver and bone metastasis possibly in response to the protein expression changes detailed above... - Current status of treatment for patients with metastatic prostate cancerCelestia S Higano
Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
Can J Urol 12:38-41. 2005..For the present, clinicians must consider many factors in determining what treatment is appropriate for the individual patient with advanced prostate cancer... - Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinicianCelestia S Higano
Department of Medicine and Department of Urology, University of Washington, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA 98109, USA
Urol Clin North Am 31:331-52. 2004..Continuing trials may give us guidance in the future... - Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)Catherine M Tangen
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
J Urol 188:1164-9. 2012..We also assessed whether any patient subsets benefited differentially during this period... - Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu
University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Urol 188:103-9. 2012..We investigated this screening failure rate to promote better classification of patients thought to have nonmetastatic castration resistant prostate cancer and inform the design of future clinical trials in this setting... 
New treatment options for patients with metastatic castration-resistant prostate cancerCelestia S Higano
University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Cancer Treat Rev 38:340-5. 2012....- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCelestia S Higano
Department of Oncology and Urology, University of Washington, Seattle, WA, USA
Cancer 115:3670-9. 2009..The safety and efficacy of sipuleucel-T was evaluated in 2 identically designed, randomized, double-blind, placebo-controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer... - Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancerIlona N Holcomb
Divisions of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
Cancer Res 69:7793-802. 2009..Our investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer... - Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?Celestia S Higano
University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Nat Clin Pract Urol 5:24-34. 2008..Future studies should address the long-term impact of antiresorptive therapy on actual fracture rate and the impact on quality of life and healthcare costs... - Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to boneMartine P Roudier
Department of Urology, University of Washington, and Puget Sound VA Medical Center, Seattle, 98195, USA
Hum Pathol 34:646-53. 2003..Consequently, therapy directed to the phenotype of 1 metastasis may have no effect on other metastases in the same patient because of phenotypic heterogeneity... - Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano
Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
Cancer 113:975-84. 2008..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)... - Does chemotherapy have a role before hormone-resistant disease develops?James P Dean
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Curr Urol Rep 10:226-35. 2009..This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy... - Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot studyMonique M Cherrier
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA
BMC Cancer 10:1. 2010..A common treatment option for men with prostate cancer is androgen deprivation therapy (ADT). However, men undergoing ADT may experience physical side effects, changes in quality of life and sometimes psychiatric and cognitive side effects... - Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to boneCelestia S Higano
Medicine and Urology, University of Washington Medical Center, Division of Medical Oncology, Seattle, WA 98109, USA
Clin Genitourin Cancer 6:40-5. 2008..The safety and tolerability of repetitive doses of the boneseeking radiopharmaceutical samarium-153 lexidronam (153Sm- EDTMP) were investigated in men with hormone-naive prostate cancer metastatic to bone... - Intermittent androgen deprivation: clinical experience and practical applicationsJonathan L Wright
Department of Urology, University of Washington, Seattle, WA 98195, USA
Urol Clin North Am 33:167-79, vi. 2006..This article discusses the theoretical benefits and rationale of IAD and reviews the completed and on-going IAD trials. Finally, the controversies, practical applications, and future directions of IAD are addressed... - Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexiaZejing Wang
Department of Urology, University of Washington, Seattle, WA 98195, USA
Int J Cancer 105:123-9. 2003..Our results demonstrated that human CaP cells express HCAP and the expression of HCAP is associated with the progression of CaP and the development of CaP cachexia... - Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15Chung Ying Huang
Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
Clin Cancer Res 13:5825-33. 2007..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance... - C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu
Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Clin Nucl Med 36:192-8. 2011.... - Positive surgical margins: the argument for androgen deprivation and chemotherapyCelestia S Higano
Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Urol Oncol 27:89-91. 2009.... - New and emerging agents for the treatment of castration-resistant prostate cancerCelestia S Higano
Department of Medicine, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Urol Oncol 29:S1-8. 2011..These realities make clinical trial design more challenging than ever... - Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerCelestia S Higano
University of Washington Medical Center, Seattle, Washington 98109, USA
Clin Cancer Res 10:1219-25. 2004..In the first cycle, patients were randomized to FL or placebo. All patients received open-label FL during the next five courses. DC, anti-FL antibody, and PSA levels were measured every 15 days to assess biological activity... - PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineMartin A Cheever
Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA
Clin Cancer Res 17:3520-6. 2011..The preclinical and clinical development of sipuleucel-T is reviewed, and approaches to enhance efficacy are considered herein... - Bone loss and the evolving role of bisphosphonate therapy in prostate cancerCelestia S Higano
Departments of Medicine and Urology, University of Washington School of Medicine, Seattle, WA 98109, USA
Urol Oncol 21:392-8. 2003..Whether zoledronic acid or other bisphosphonates might actually prevent or delay the development of bone metastases remains to be studied in randomized clinical trials... - Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 170:S3-5. 2003 - Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cellsJames D Lord
Department of Medicine, University of Washington, Seattle, WA, USA
Dig Dis Sci 55:1396-405. 2010..However, we found no evidence of FOXP3(+) T cell depletion in any of the nine patients who developed colitis... - Management of bone loss in men with prostate cancerCelestia S Higano
Seattle Cancer Care Alliance, University of Washington, 98109, USA
J Urol 170:S59-63; discussion S64. 2003..Skeletal metabolism and osteoporosis in men, assessment of bone mineral density (BMD), effects of ADT on BMD, management strategies and potential therapies for osteopenia or osteoporosis in men with prostate cancer are reviewed... - Elevation of cytokine levels in cachectic patients with prostate carcinomaJesco Pfitzenmaier
Department of Urology, University of Washington, Seattle, Washington 98195, USA
Cancer 97:1211-6. 2003..Additional fundamental research is needed to determine the mechanisms involved and to identify potential therapeutic targets in patients with cachexia... - Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancerEva Corey
Department of Urology, University of Washington, Seattle, Washington 98195, USA
Clin Cancer Res 9:295-306. 2003..In this study we have examined the effects of zoledronic acid (ZA), a new-generation bisphosphonate, on prostate cancer (CaP) cells in vitro, and on both osteoblastic and osteolytic CaP metastases in animal models... - Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancerMatthew R Smith
Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
J Clin Oncol 23:2918-25. 2005..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy... - Annual zoledronic acid: is less more?Celestia S Higano
J Clin Oncol 25:1026. 2007 - Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett
The Johns Hopkins Hospital, 600 North Wolfe St, Marburg 407, Baltimore, Maryland 21287 2411, USA
J Urol 178:597-601. 2007.... - Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley
Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
J Urol 180:1432-7; discussion 1437. 2008..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy... - Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapiesTerrence H Diamond
Department of Medicine, University of New South Wales, St George Hospital Campus, Sydney, Australia
Cancer 100:892-9. 2004..In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT... - A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapyJames L Gulley
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 173:1567-71. 2005..We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy... - Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancerTomasz M Beer
Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Clin Cancer Res 10:1306-11. 2004..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence... - Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelTomasz M Beer
Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Invest New Drugs 25:565-70. 2007..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity... - Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancerMark Garzotto
Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
Urol Oncol 24:254-9. 2006..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy... - The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panelFred Saad
Universite de Montreal, Quebec, Canada
Clin Genitourin Cancer 4:257-62. 2006..However, further study of the use of bisphosphonates across the clinical spectrum of prostate cancer is needed... - Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reMichael S Cookson
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
J Urol 177:540-5. 2007.... - Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
J Clin Oncol 25:669-74. 2007..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel... - Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson
American Urological Association Education and Research, Inc
J Urol 177:2106-31. 2007 - Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancerTomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Clin Genitourin Cancer 5:329-33. 2007..We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in patients receiving systemic therapy for prostate cancer... - American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancerEthan M Basch
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:5313-8. 2007..The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer... - Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small
UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
J Clin Oncol 24:3089-94. 2006..A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study...